Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2022-06-16 / BMJ Open 2022 Jun;12(6):e060431Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field
/in Hyperthermia, International Publications /von 2022-06-04 / Cells 2022 Jun;11(11)Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2022-06-03 / Cancer Immunol Res 2022 Jun;10(6):728-744Poster presentation at the International Symposium on Pediatric Neuro-Oncology
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)Poster presentation at the annual meeting of the Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution